News

Which paclitaxel schedule works best for breast cancer?


 

AT THE ASCO ANNUAL MEETING 2013

CHICAGO – Dr. G. T. Budd, of the Cleveland Clinic, discusses the efficacy, side effects, and costs of giving paclitaxel weekly vs. every 2 weeks when treating breast cancer. Dr. Budd discussed trial results comparing the schedules in an interview at the annual meeting of the American Society of Clinical Oncology.

Recommended Reading

Smaller margins too close for comfort in breast cancer
MDedge Hematology and Oncology
Online cancer community colaunched by ex-Google executive
MDedge Hematology and Oncology
Genetic tests gauge breast-cancer recurrence risk
MDedge Hematology and Oncology
Cancer-cell reprogramming poses new treatment challenge
MDedge Hematology and Oncology
Intratumor heterogeneity drives need for multiple biopsies
MDedge Hematology and Oncology
New imaging promises improved breast cancer utility
MDedge Hematology and Oncology
Resistance exercise interventions during and following cancer treatment: a systematic review
MDedge Hematology and Oncology
Utilization of radiotherapy services by a palliative care unit: pattern and implication
MDedge Hematology and Oncology
ASCO guidelines for fertility preservation affirm oocyte preservation
MDedge Hematology and Oncology
10 years of tamoxifen halves risk of death from breast cancer
MDedge Hematology and Oncology